Ahead of adcomm, FDA questions efficacy of Alnylam's patisiran in disabling rare condition ATTR-CM
The FDA’s Cardiovascular and Renal Drugs Advisory Committee will meet tomorrow to discuss the efficacy of Alnylam’s Onpattro (patisiran) for the treatment of cardiomyopathy of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
